Lee Yu-Kai, Parks Daniel J, Lu Tianbao, Thieu Tho V, Markotan Thomas, Pan Wenxi, McComsey David F, Milkiewicz Karen L, Crysler Carl S, Ninan Nisha, Abad Marta C, Giardino Edward C, Maryanoff Bruce E, Damiano Bruce P, Player Mark R
Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, Pennsylvania 19477-0776, USA.
J Med Chem. 2008 Jan 24;51(2):282-97. doi: 10.1021/jm701217r. Epub 2007 Dec 27.
We have developed a novel series of potent and selective factor Xa inhibitors that employ a key 7-fluoroindazolyl moiety. The 7-fluoro group on the indazole scaffold replaces the carbonyl group of an amide that is found in previously reported factor Xa inhibitors. The structure of a factor Xa cocrystal containing 7-fluoroindazole 51a showed the 7-fluoro atom hydrogen-bonding with the N-H of Gly216 (2.9 A) in the peptide backbone. Thus, the 7-fluoroindazolyl moiety not only occupied the same space as the carbonyl group of an amide found in prior factor Xa inhibitors but also maintained a hydrogen bond interaction with the protein's beta-sheet domain. The structure-activity relationship for this series was consistent with this finding, as the factor Xa inhibitory potencies were about 60-fold greater (DeltaDelta G approximately 2.4 kcal/mol) for the 7-fluoroindazoles 25a and 25c versus the corresponding indazoles 25b and 25d. Highly convergent synthesis of these factor Xa inhibitors is also described.
我们开发了一系列新型的强效且选择性的凝血因子Xa抑制剂,这些抑制剂采用了关键的7-氟吲唑基部分。吲唑支架上的7-氟基团取代了先前报道的凝血因子Xa抑制剂中酰胺的羰基。含有7-氟吲唑51a的凝血因子Xa共晶体结构显示,7-氟原子与肽主链中Gly216的N-H形成氢键(2.9 Å)。因此,7-氟吲唑基部分不仅占据了先前凝血因子Xa抑制剂中酰胺羰基所占据的相同空间,还与蛋白质的β-折叠结构域保持氢键相互作用。该系列的构效关系与这一发现一致,因为与相应的吲唑25b和25d相比,7-氟吲唑25a和25c的凝血因子Xa抑制效力大约高60倍(ΔΔG约为2.4 kcal/mol)。还描述了这些凝血因子Xa抑制剂的高度收敛合成方法。